Barclays
LKFT icon

Barclays’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Barclays’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40.1K Buy
1,353
+1,234
+1,037% +$35.4K ﹤0.01% 4623
2026
Q2 		$3.57K Sell
119
-59
-33% -$1.68K ﹤0.01% 4811
2026
Q1 		$5.34K Sell
178
-2,177
-92% -$72.1K ﹤0.01% 4766
2025
Q4 		$77K Sell
2,355
-36,647
-94% -$1.18M ﹤0.01% 4648
2025
Q3 		$1.35M Sell
39,002
-1,167
-3% -$37.3K ﹤0.01% 3184
2025
Q2 		$1.12M Buy
40,169
+8,309
+26% +$223K ﹤0.01% 3266
2025
Q1 		$800K Buy
31,860
+31,029
+3,734% +$784K ﹤0.01% 3239
2024
Q4 		$22.9K Buy
831
+731
+731% +$20.4K ﹤0.01% 4906
2024
Q3 		$2.88K Buy
+100
New +$2.72K ﹤0.01% 5062
2023
Q4 		– Sell
-6,200
Closed -$228K – 5264
2023
Q3 		$214K Buy
+6,200
New +$241K ﹤0.01% 3265
2022
Q2 		– Sell
-19,772
Closed -$1.23M – 5116
2022
Q1 		$1.23M Buy
19,772
+11,511
+139% +$705K ﹤0.01% 2243
2021
Q4 		$455K Hold
8,261
– – ﹤0.01% 3249
2021
Q3 		$435K Hold
8,261
– – ﹤0.01% 3254
2021
Q2 		$569K Sell
8,261
-6
-0.1% -$458 ﹤0.01% 3011
2021
Q1 		$637K Buy
+8,267
New +$762K ﹤0.01% 3052
2020
Q3 		– Sell
-6,900
Closed -$1.36M – 5332
2020
Q2 		$1.36M Buy
+6,900
New +$1.43M ﹤0.01% 2472
2020
Q1 		– Sell
-58,408
Closed -$12.1M – 6249
2019
Q4 		$12.1M Buy
58,408
+45,143
+340% +$8.35M 0.01% 1261
2019
Q3 		$2.03M Buy
13,265
+9,409
+244% +$1.54M ﹤0.01% 2849
2019
Q2 		$497K Sell
3,856
-4,693
-55% -$557K ﹤0.01% 4324
2019
Q1 		$1.01M Buy
8,549
+8,500
+17,347% +$857K ﹤0.01% 3394
2018
Q4 		$4K Sell
49
-467
-91% -$47.3K ﹤0.01% 6516
2018
Q3 		$58K Buy
516
+423
+455% +$44.7K ﹤0.01% 5987
2018
Q2 		$8K Hold
93
– – ﹤0.01% 6612
2018
Q1 		$9K Buy
93
+77
+481% +$8.3K ﹤0.01% 6680
2017
Q4 		$2K Sell
16
-4,398
-100% -$416K ﹤0.01% 6777
2017
Q3 		$449K Buy
+4,414
New +$386K ﹤0.01% 3722
2015
Q3 		– Sell
-2,300
Closed -$117K – 6909
2015
Q2 		$117K Buy
+2,300
New +$122K ﹤0.01% 4556

Other funds holding LKFT

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Crossmark Global Holdings
Crossmark Global Holdings Houston, Texas $7.69B AUM 31.68% 1-Year Est. Return
MQS Management
MQS Management New York $171M AUM 3.86% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Evergreen Capital Management
Evergreen Capital Management Bellevue, Washington $5.65B AUM 21.62% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Cacti Asset Management
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return

Barclays's LKFT Position: Q3 2026 in Review

Barclays increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 1,037% in Q3 2026, buying an estimated $35.4K and bringing the position to 1,353 shares worth $40.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4623.

Barclays first reported a position in LKFT in Q2 2015 and has held it in 27 quarters since. The position peaked at $12.1M in Q4 2019. 28 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.

  • Barclays held 1,353 shares of Lakefront Biotherapeutics American Depositary Shares worth $40.1K as of Q3 2026.
  • Barclays bought 1,234 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $35.4K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4623 holding.
  • Barclays first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 27 quarters since.
  • Barclays's Lakefront Biotherapeutics American Depositary Shares position peaked at $12.1M in Q4 2019.
  • 28 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.